Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer

L Zhang, D Jiang, C Chen, X Yang, H Lei… - The British Journal of …, 2022 - academic.oup.com
Objective: To develop and validate a non-invasive MRI-based radiomics signature for
distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy …
被引用次数：10 相关文章

Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer

L Zhang, D Jiang, C Chen, X Yang… - The British journal …, 2022 - pubmed.ncbi.nlm.nih.gov
Objective To develop and validate a non-invasive MRI-based radiomics signature for
distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy …

Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer.

L Zhang, D Jiang, C Chen, X Yang, H Lei… - The British Journal of …, 2021 - europepmc.org
Objective To develop and validate a non-invasive MRI-based radiomics signature for
distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy …
[HTML] nih.gov

[HTML][HTML] Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer

L Zhang, D Jiang, C Chen, X Yang, H Lei… - The British Journal of …, 2022 - ncbi.nlm.nih.gov
Objective: To develop and validate a non-invasive MRI-based radiomics signature for
distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy …

Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer

L Zhang, D Jiang, C Chen, X Yang, H Lei, Z Kang - academic.oup.com
Objective: To develop and validate a non-invasive MRI-based radiomics signature for
distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy …

Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer.

L Zhang, D Jiang, C Chen, X Yang, H Lei… - The British Journal of …, 2021 - europepmc.org
Objective To develop and validate a non-invasive MRI-based radiomics signature for
distinguishing between indolent and aggressive prostate cancer (PCa) prior to therapy …